Merck Moves Fall Flat
The third Vioxx trial starts Tuesday in a federal courthouse in Houston. Merck lost a state-court case in Texas in August and won a state-court case in New Jersey in early November. As of Sept. 30, Merck said more than 6,400 U.S. lawsuits had been filed claiming Vioxx had caused an injury or a death.
For 2006, Merck expects to earn $2.28 to $2.36 a share, excluding restructuring charges, but including an expense of 7 cents for expensing stock options. The estimates exclude potential Vioxx liability reserves. The consensus forecast is $2.38 a share.
When calculated using generally accepted accounting principles, Merck predicts 2005 earnings of $2.04 to $2.10 and a 2006 profit of $1.98 to $2.12.
The company said its manufacturing overhaul should enable gross profit margins after 2008 to return to the level seen before the loss of Zocor's U.S. market exclusivity. The cholesterol drug, which has been losing patent protection in some foreign markets, will be hit by generics in the U.S. in June.Zocor had $5.2 billion in worldwide sales last year. Merck expects sales to be $4.2 billion to $4.5 billion this year, before falling to $2.3 billion to $2.6 billion in 2006.
The New PlanThe new manufacturing plan will cost $350 million to $400 million this year and $800 million to $1 billion next year. Through the end of 2008, Merck sees cumulative pretax costs of $1.8 billion to $2.2 billion, with about70% being noncash expenses related to accelerated depreciation of the closed plants. Barbara Ryan, of Deutsche Bank Securities, says the Merck restructuring appears to be less aggressive than the plan at Pfizer (PFE). She doesn't own shares, but her firm says it does and seeks to do business with companies mentioned in research reports. Pfizer has said it wants to produce $4 billion in cost savings a year by 2008. Pfizer said it expects to save $400 million this year, $2 billion next year, $3.5 billion in 2007 and $4 billion in 2008. The cost of implementing the restructuring could be as much as $5 billion over four years. Additionally, Pfizer has announced plans to shed six plants and several smaller facilities. Pfizer wants to cut by 25% the number of worldwide plants it has. The changes will lead to job losses, but Pfizer executives say they'll inform employees of specific reductions before they tell Wall Street. Merck also cut its estimate of 2005 capital spending by $100 million to $1.4 billion and said expenditures will fall another $100 million next year. Total capital spending from 2005 to 2008 will likely be about $1.3 billion below the company's expectations for long-range capital spending at the end of 2004, Merck said. The new estimates are on top of a previously announced $600 million reduction. One goal of the plan is to bring new drugs to market faster. The company will identify certain facilities "that will support production needs from late-phase clinical trials through the launch phase," trying to cut 12 to 15 months from the product-launch process.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV